logo
Worcester County names two finalists for next superintendent of schools. Meet them here.

Worcester County names two finalists for next superintendent of schools. Meet them here.

Yahoo09-04-2025

The Worcester County Board of Education has announced the names of the two finalists for the next Worcester County Superintendent of Schools. Each finalist will participate in a 'Day in the District' experience later this month.
Here are the finalists, in alphabetical order, and their biographies provided by Worcester County Public Schools.
Annette Wallace – A graduate of Worcester County Public Schools, Annette Wallace currently serves as WCPS Chief Safety Officer and Academic Officer for grades 9-12. With a history of impactful leadership, Wallace served as principal of Pocomoke High School from 2012-2018, where she doubled AP enrollment while significantly improving student pass rates and launched Project 100 to increase access to post-secondary education, all of which led to the school becoming the district's highest performing. Since her appointment to Chief Operating Officer in 2018, Wallace has demonstrated leadership in school construction, food services, technology, special education, all academic content areas, human resources, and student services. She holds degrees in Mathematics, School Leadership, and Educational Leadership, is actively involved in her community, and has presented as a thought leader at local, state, and national education conferences.
Monique Wheatley-Phillip – Monique Wheatley-Phillip brings over 30 years of experience in education, including 17 years in Title I schools as a classroom and special education resource teacher. She has led medium and large sized schools and annually supervised over 30 principals who served in diverse communities. As the Baltimore County Public Schools Division Chief of Research, Accountability, and Assessment, she supervised the development of the eight-year strategic plan, which identified annual goals and specific targets for the system. A strategic thinker and planner who understands the importance of collaboration and gaining consensus, Wheatley-Phillip's expertise in the use of evidence-based instructional practices and data analytics narrowed achievement gaps and increased performance across student groups. In her current role as a Consulting Administrator, School Operations, Wheatley-Phillip supports schools by managing the utilization of $11 million dollars of extracurricular and co-curricular activity funds. Additionally, she manages seven million dollars in Title II grant funds that support educator development. She holds degrees in education as well as certificates in Leadership and Reading.
'The search process to find a new educational leader in Worcester County has been a top priority for this Board. We are pleased with our progress in the search so far, and we are excited to announce our two highly qualified finalists,' Board of Education President Todd Ferrante said. 'We greatly appreciate the investment our community is making by participating in the upcoming focus groups and providing input to the Board. We look forward to making a final decision soon and helping our new Superintendent create a vision and plan for transitioning into this leadership role.'
The Board's goal is to choose the top candidate for superintendent this month and vote to appoint the chosen candidate in May. The new superintendent would begin on July 1, 2025.
Shore has new businesses all around: New businesses galore: Insomnia Cookies, BBQ/sushi spot, juice shop | What's Going There
In January, Superintendent Lou Taylor announced he would not seek another reappointment to another four-year term, choosing instead to retire after his 41 years of service to the school system. Following Taylor's announcement, the Board of Education contracted with the Maryland Association of Boards of Education (MABE) to conduct the search process. Public input was gathered in February to inform the search process for a new superintendent. Participants were asked to describe the characteristics they sought in a new Superintendent. This Superintendent profile was used when reviewing candidate qualifications.
In March, the superintendent opening was posted widely so that qualified local, state, and national candidates could apply, with the first consideration of applications on March 26. The Board conducted interviews to select the finalists who will participate in the extensive interviews April 22 – 23, with various stakeholder groups. These groups will provide input to the Board as it prepares to choose a new superintendent.
Each of the finalists' 'Day in the District' will include time to meet with local officials; interviews with panels of CentralOffice leaders, principals, teachers, support staff, business leaders, parents and community leaders; lunch with students;time to meet with members of the media; and dinner and discussion with the Board of Education.
Player of the Week nominees: Here are the Delmarva Now Player of the Week nominees for Mar. 31-Apr. 6
This article originally appeared on Salisbury Daily Times: Meet Worcester's two finalists for next superintendent of schools

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Regarding the New Wording of Draft Resolutions for the General Meeting of Shareholders Convened on 30 June 2025
Regarding the New Wording of Draft Resolutions for the General Meeting of Shareholders Convened on 30 June 2025

Yahoo

time3 hours ago

  • Yahoo

Regarding the New Wording of Draft Resolutions for the General Meeting of Shareholders Convened on 30 June 2025

AB PST Group (hereinafter, the 'Company'), taking into consideration that: (i) at the extraordinary general meeting of shareholders of the Company, to be held at 10:00 a.m. on 30 June 2025, being convened at the initiative and decision of the Board of the Company, it is intended to consider the issue to delist all the outstanding shares of the Company from trading on the regulated market AB Nasdaq Vilnius (hereinafter, the 'Meeting'); (ii) in its notification about the intention to delist the shares of the Company from trading on the regulated market AB Nasdaq Vilnius the Board of the Company, among other things, recommended to its shareholders, who intend to vote 'for' the decision do delist the shares of the Company from trading on the regulated market AB Nasdaq Vilnius, to provide their draft resolutions on the items of the agenda of the Meeting; (iii) on 28 May 2025 the shareholder of the Company AB 'HISK' (hereinafter, the 'Shareholder') has provided to the Company the draft decisions of the Meeting, which were announced by the Company; (iv) on 9 June 2025, the Shareholder provided one more letter with new draft resolutions of the agenda items of the Meeting (hereinafter, the 'New Draft Resolutions'), whereby, taking into consideration the circumstances, indicated in the letter, offers to the Meeting to foresee higher price of the tender offer aimed at delisting the shares of the Company from trading on the regulated market AB Nasdaq Vilnius than it was offered by the draft decisions, provided on 28 May 2025 (EUR 0.760 instead of EUR 0.735), hereby announces the following New Draft Resolutions for the Meeting, proposed by the Shareholder: 1. Delisting of shares of the Company from trading on the regulated market AB Nasdaq Vilnius. Draft resolution: 1.1. To initiate delisting of all the outstanding shares of the Company and to delist them from trading on the regulated market AB Nasdaq Vilnius. 1.2. Although Article 33(7) of the Law of the Republic of Lithuania on Securities foresees that the shareholders, who voted 'for' the decision to delist the shares of the company from trading on the regulated market are obliged to submit the tender offer aimed at delisting the shares of the company from trading on the regulated market, however, aiming to provide the shareholders with a possibility to vote 'for' this decision without gaining the obligation to submit the tender offer and still maintaining the right to participate in the tender offer and also further maintaining the right to sell the shares held in the Company during the tender offer, to establish that: - only the shareholder of the Company AB 'HISK', having voted 'for' the decision to delist the shares of the Company from trading on the regulated market AB Nasdaq Vilnius, will under the procedure set by legal acts submit the circular of the tender offer aimed at delisting the shares of the Company from trading on AB Nasdaq Vilnius to the Bank of Lithuania for approval and will implement the indicated tender offer for the price, established following the principles, indicated in item 1.3 hereof; - during the effective term of this tender offer, the right, but not the obligation, to sell the shares will be vested in all the shareholders of the Company, except for AB 'HISK'; - the decisions of this general meeting of shareholders of the Company regarding delisting of shares of the Company from trading on the regulated market AB Nasdaq Vilnius and regarding submission and implementation of the related tender offer is valid only if the price of the tender offer is not higher than established by the decision 1.3 of this meeting. 1.3. The price of the tender offer aimed at delisting the shares of the Company from trading on AB Nasdaq Vilnius will be set in accordance with item 1 of paragraph 1 of Article 29 of the Law of the Republic of Lithuania on Securities, which is EUR 0.553, adding 37,5% premium to the fair price, established under these principles, i. e., to set that the tender offer price shall be EUR 0.760 for single share of the Company. 2. Authorizing the manager of the Company. Draft resolution: To authorise and oblige the Manager of the Company (General Manager) with the right to delegate, after the relevant Company's shareholders shall implement the tender offer aimed at delisting the shares of the Company from trading on AB Nasdaq Vilnius, to carry out necessary actions and to submit necessary documents to AB Nasdaq Vilnius on delisting of the shares of the Company from trading on this regulated market. Upon request of the Shareholder, taking into consideration that all the New Draft Resolutions, comply with the drafts, provided on 28 May 2025, only except item 1.3 of the draft resolution, according to which the offered Tender Offer price is increased from EUR 0.735 to EUR 0.760, wherefore the conditions of all the minority shareholders of the Company are being improved during the tender offer (and it would be not beneficial for them to vote for the draft decision dated 28 May 2025 with the lesser price), the Company provides the Meeting for voting with only the New Draft Resolutions, presented by the letter of the Shareholder, dated 9 June 2025, indicated above. The Company also informs that its Management Board does not have and will not provide any alternative draft resolutions to the Meeting on its agenda items. ATTACHED: - Letter of the shareholder AB 'HISK' regarding provision of New Draft Decisions of the Meeting.- General voting ballot. For more information:Tomas StukasManaging Director of AB PST GroupTel.: +370 618 21360 Attachments AB HISK Rastas II (del sprendimu projektu pateikimo) (LT-EN) General ballot paper 2025-06-30 (updated)_ENError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Yahoo

time6 hours ago

  • Yahoo

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Yahoo

time6 hours ago

  • Yahoo

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store